-
Mashup Score: 1CheckMate 67T and the Potential of Subcutaneous Nivo Administration | GU Oncology Now - 2 month(s) ago
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Source: guoncologynow.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1CheckMate 67T and the Potential of Subcutaneous Nivo Administration | GU Oncology Now - 2 month(s) ago
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Source: guoncologynow.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1CheckMate 67T and the Potential of Subcutaneous Nivo Administration | GU Oncology Now - 3 month(s) ago
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Source: guoncologynow.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Approves Adjuvant Nivolumab for Resected, Stage IIB/C Melanoma - 7 month(s) ago
Based on findings from the phase 3 CHECKMATE-76K trial, the FDA has approved nivolumab in the adjuvant setting for patients 12 and older with completely resected stage IIB/C melanoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Immune checkpoint inhibitors (ICIs) have entailed a radical change in the therapeutic landscape of multiple tumors. The ICIs enhance immunogenic activity against tumor cells through suppression of negative signaling over cytotoxic T cells. Nivolumab is a fully human immunoglobulin G4 antibody that blocks the interaction between programmed cell death protein-1 (PD-1) and its corresponding ligand. Interfering with physiological mechanisms of peripheral immune tolerance conducts intensified systemic immune response, which enhances antitumor activity, but also favors inflammation leading to a wide spectrum of immune-related adverse effects (irAEs).
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC - 7 month(s) ago
“Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a dent on the natural history of the disease for these patients.”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6
The addition of nivolumab to chemotherapy improves survival in patients with advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal ju…
Source: www.sciencedirect.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Nivolumab Plus BTK Inhibitor Ibrutinib Demonstrates Activity, Safety Among Patients With DLBCL Richter Transformation - 9 month(s) ago
According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Unlocking Cancer Treatment: Nivolumab & Ipilimumab Explored - 9 month(s) ago
In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Sitravatinib, a receptor tyrosine kinase inhibitor targeting TYRO3, AXL, MERTK receptors, and vascular epithelial growth factor receptor 2, can shift the tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with checkpoint inhibitors (CPIs) may augment antitumor activity.
Source: www.jto.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
With the goal of augmenting antitumor activity, the authors combined #sitravatinib w/#nivolumab every 2 or 4 wks in pts w/advanced nonsquamous #NSCLC. They found that this combination had a manageable safety profile & exhibited antitumor activity. https://t.co/zlLRImZo0d #LCSM https://t.co/yOBJkMtZfc
-
🎙️ Catch the latest segment of our roundtable discussion with @DrRanaMcKay, @katy_beckermann, @HHammersMD, and Nizar Tannir, MD, on the potential of subcutaneous #nivolumab administration. Watch Now: https://t.co/WXcNIALRI8 https://t.co/DBTpSuCidQ